Introduction
In the past 5 years, the general interest in studying the RET proto-oncogene has been growing exponentially. The RET proto-oncogene encodes a receptor-type tyrosine kinase with an extracelluar domain, a transmembrane domain, and an intracellular tyrosine kinase domain (reviewed in Itoh et al., 1989) . The ligands for RET have been recently identi®ed as neurotrophic factors of the glial cell-line derived neurotrophic factor (GDNF) family, including GDNF, neurturin, artemin, and persephin. All these factors activate RET via dierent glycosyl phosphatidylinositol-linked GFRa receptors (reviewed in Airaksinen et al., 1999; Baloh et al., 2000) . The clinical relevance of RET in human diseases was ®rst recognized in papillary thyroid carcinoma (PC), followed by multiple endocrine neoplasia type 2 (MEN 2), sporadic tumors involved in MEN 2, and then Hirschprung's disease. In addition, there are ample interests to explore the possibility of using RET ligands as potential therapeutic agents for a variety of neurodegenerative diseases. Taken together, the characterization of RET-mediated signaling pathways is not only important for tumor biology and developmental biology, it is also of clinical signi®cance to elucidate the molecular mechanism(s) underlying the potential therapeutic eects of RET ligands in neurodegenerative diseases. However, in this review, I will mainly focus on clinical observations as well as biochemical and functional studies of RET activation in human PCs and MEN 2 cancers.
RET/PTC and papillary thyroid carcinomas
The RET/PTC oncogenes are rearranged forms of the RET proto-oncogene detected in human papillary thyroid carcinomas (PCs). As shown in Figure 1 , several dierent activating genes, H4 (D10S170 locus), RIa, ELE1, RFG5 (golga5), HTIF, RFG7 and ELKS, have been shown to rearrange with RET to form RET/ PTC1, RET/PTC2, RET/PTC3 (or RET/PTC4), RET/ PTC5, RET/PTC6, RET/PTC7, and RET/ELKS, respectively (reviewed in Santoro et al., 1999; Klugbauer and Rabes, 1999; Nakata et al., 1999) . In each case, the intracellular domain of RET, which has tyrosine kinase activity, is fused to the N-terminus of the activating gene that is capable of ligand-independent dimerization. Therefore, RET/PTC is activated by constitutive dimerization. We and others have shown that the constitutive dimerization of RET/PTC is essential for its transforming activity in vitro. In contrast to RET, RET/PTC does not have a transmembrane domain, and thus is not an integral membrane protein. However, Durick et al. (1998) showed that the interaction of RET/PTC2 with Enigma may be responsible for the localization of RET/PTC to the cell periphery. Since all the activating genes are constitutively expressed in thyroid follicular cells, the RET/PTC chimeric oncogenes are constitutively expressed and activated in thyroid follicular cells.
Dierentiated thyroid tumors derived from thyroid follicular cells in humans are subdivided into papillary and follicular thyroid carcinomas. These two tumor types have dierences in cytological nuclear features, etiology, clinical behavior, and oncogene involvement. To date, the pathogenetic mechanisms underlying the dierences in these two tumor types are not understood. The unique involvement of RET/PTC in PCs suggests that signaling cascades activated by RET/PTC may have a direct contribution to the clinical properties observed in PCs. Indeed, we have shown that targeted expression of RET/PTC1 in the thyroid gland leads to the development of thyroid tumors in transgenic mice with histologic and cytologic similarities to human PCs Sagartz et al., 1997) . In cultured normal human thyroid follicular cells, expression of RET/PTC induces small, poorlydemarcated colonies with a morphology consistent with early PCs (Bond et al., 1994) . RET/PTC expression in primary cultures of human thyroid epithelial cells results in changes in nuclear morphology with an irregular nuclear contour and an euchromatic appearance, which are diagnostic of PCs (Fischer et al., 1998) . These data support the hypothesis that the signaling cascades activated by RET/PTC do have a direct contribution to the clinical properties observed in PCs.
Many attempts have been made to correlate the presence of RET/PTC activation with the clinical parameters of human PCs. While the incidence of RET/PTC activation in spontaneous PCs ranges from 5 ± 30% (Jhiang and Mazzaferri, 1994) , the incidence of RET/PTC activation in radiation-induced PCs is in the range of 60 ± 70% (Klugbauer et al., 1995; Rabes et al., 2000) . Indeed, it has been shown that RET/PTC activation can be induced by irradiation in cultured cells as well as in human thyroid tissues implanted in SCID mice (Mizuno et al., 2000) . Moreover, RET/ PTC3 seems to be associated with PCs of solid variant and childhood PCs of short latency from areas contaminated by the Chernobyl nuclear reactor accident (Nikiforov et al., 1997; Thomas et al., 1999; Smida et al., 1999) . In contrast, RET/PTC1 is the major form found in spontaneous PCs, in PCs associated with therapeutic external radiation, and in childhood PCs of long latency from areas contaminated by the Chernobyl nuclear reactor accident (Bounacer et al., 1997; Smida et al., 1999) . However, the prognostic value of RET/PTC in PCs remains controversial. We have shown that RET/PTC was more commonly found in PCs from patients with metastases (Jhiang et al., 1992) . The ®ndings that RET/ PTC is frequently detected in post-Chernobyl PCs that are characterized with a short latency and histologic features associated with aggressive biological behavior further support the notion that RET/PTC may serve as a poor prognostic factor. However, other investigators have shown that RET/PTC was more frequently detected in smaller, slow growing, and less aggressive PCs, arguing that RET/PTC may serve as a marker for favorable prognosis (Soares et al., 1998; Tallini et al., 1998) . This discrepancy may be explained by the dierences in screening methods, sample preparation, genetic background of patients, and environmental factors.
Many studies screened for the presence of RET/PTC oncogenes in thyroid samples merely by reverse transcription-polymerase chain reaction (RT ± PCR) and/or immunohistochemical staining. Immunohistochemical staining using antibodies against the RET tyrosine kinase domain for the detection of RET/PTC in PCs is based on the assumption that RET is not expressed in thyroid follicular cells lacking RET/PTC activation. However, the speci®city of the antibodies to recognize the`RET-speci®c' tyrosine kinase domain has not been thoroughly investigated. RT ± PCR is a sensitive method to detect RET/PTC chimeric transcripts, yet it is easily plagued by carry-over contamination. Since it is unlikely that dierent PCs would have an identical breakpoint in RET/PTC, it is desirable to exclude the possibility of carry-over contamination by amplifying the chimeric introns and characterizing the breakpoints among PCs shown positive for RET/PTC. A recent report using interphase FISH to detect RET rearrangement, in conjunction with RT-PCR to con®rm the presence and the type of chimeric transcripts, seems to be an attractive alternative method (Cinti et al., 2000) . Taken together, using an eective and reliable strategy to screen for RET/PTC in thyroid samples is instrumental in resolving the discrepancy concerning the prognostic value of RET/PTC in human PCs.
Furthermore, the presence of a particular type of RET/PTC activation may not provide the necessary information for prognosis. It is also pertinent to investigate the biological consequences of the expression levels of RET/PTC in PCs. While all activating genes for RET/PTC oncogenes are ubiquitously expressed, their expression levels in thyroid follicular cells may be subject to regulation by dierent phases of the cell cycle, dierent developmental stages, and dierent physiological conditions. Therefore, the microenvironments and the cellular conditions of thyroid follicular cells when RET/PTC is activated may play a signi®cant role in the development and progression of human PCs. Furthermore, the dierences in the N-terminal portion of RET/PTC oncoproteins may contribute to dierences in their biological eects. Indeed, The RET/PTC1 variant with an additional 49 amino acid residues of H4 has a lower transforming activity compared to RET/PTC1 in NIH3T3 cells . The clinical properties of PCs with RET/PTC3 seem to be dierent from those with RET/PTC1. Therefore, a better understanding of the molecular and cellular mechan- Figure 1 Schematic representation of the wild-type RET protein and RET/PTC chimeric oncoproteins found in human papillary thyroid carcinomas. The breakpoint location is represented by a black arrow. The transmembrane domain (TM), tyrosine kinase domain (TK), coiled-coil domain (CC), PTC2 cysteine residues forming disul®de bonds during dimerization (C18, C39), ring ®nger domain (RF), b1 and b2 box domains (b1, b2), phd ®nger domain (phd), and the bromodomain (Br) are indicated isms underlying RET/PTC-induced thyroid tumorigenesis will be necessary prior to the use of RET/PTC as a molecular marker to improve clinical management of human PCs.
The biological eects of RET/PTC activation in thyroid follicular cells have been investigated in cultured cells as well as thyroid-targeted transgenic mice. In immortalized rat thyroid PC Cl 3 cells, RET/ PTC1 expression results in the loss of their dependence on six growth factors for growth, and the blocking of the thyroid-dierentiated phenotype (Santoro et al., 1993) by impairing the activity of TTF-1 and Pax-8 thyroid transcription factors . The cells expressing RET/PTC1 retain an epithelial morphology, showing only a few spindles and increased refractility. However, when both the RET/PTC1 and ras oncogenes were co-expressed in the PC Cl 3 cells, the fully transformed phenotype was obtained (Santoro et al., 1993) . In primary human thyrocytes, RET/PTC1 expression stimulates proliferation, induces poorly demarcated colonies with a distinctive`fenestrated' pattern, yet retains thyroglobulin expression (Bond et al., 1994) . In our high copy thyroid targeted-RET/ PTC1 transgenic mice, a slightly increased proliferation rate, distorted thyroid follicle formation, and reduced radioiodide concentrating activity were found as early as embryological day 16.5 (Cho et al., 1999) . These early cellular abnormalities induced by RET/PTC1 provide evidence for the role of RET/PTC1 in the formation of abnormal follicles with reduced iodide uptake activity observed in human PCs. The thyroid tumors which develop in thyroid-targeted RET/PTC1 transgenic mice are slow growing, TSH responsive, and do not metastasize Sagartz et al., 1997) . However, while some thyroid-targeted RET/ PTC3 transgenic mice did develop metastatic cancer (Powell et al., 1998) , dierent strains of mice were used to generate these two dierent transgenic mouse models. Therefore, while it is tempting to conclude that thyroid tumors induced by RET/PTC3 are more metastatic than thyroid tumors induced by RET/PTC1, it remains possible that the phenotypic dierences between RET/PTC1 mice versus RET/PTC3 mice are due to dierence in genetic background.
Dierent forms of RET/PTC oncogene detected in human PCs have been summarized (Figure 1 ). Constitutive dimerization leads to constitutive activation of RET/PTC in thyroid follicular cells. The cellular eects of RET/PTC activation in thyroid follicular cells include a slightly increased proliferation rate, loss of iodide concentrating activity, and aberrant follicle formation. It is well recognized that RET/PTC activation is associated with radiation-induced human PCs and that RET/PTC activation has a direct contribution to the clinical properties observed in human PCs. However, it is yet to be determined whether the clinical behavior of human PC is aected by dierences in RET/PTC expression levels, and/or the dierent forms of RET/PTC. It is conceivable that signaling pathways perturbed by RET/PTC activation in thyroid cells could be overcome by other factors, if RET/PTC expression occurs at a low level. In order to use RET/PTC as a molecular marker for the clinical management of human PCs, we must uncover (a) what signaling pathways are perturbed by RET/PTC in thyroid follicular cells, (b) how these signaling cascades lead to cellular changes seen in human PCs, and (c) which cellular changes are essential for thyroid tumorigenesis.
RET and multiple endocrine neoplasia type 2
The RET proto-oncogene was identi®ed as the susceptibility gene for multiple endocrine neoplasia type 2 (MEN 2), an inherited cancer syndrome characterized by medullary thyroid carcinoma (MTC), pheochromocytoma (Pheo), and parathyroid hyperplasia (PTH) (reviewed in Eng, 1999) . MEN 2 is further divided into three subtypes, MEN 2A, MEN 2B and FMTC, depending on the organs involved. The aected members in MEN 2A families develop MTC (100% of cases), Pheo (50% of cases), and PTH (15 ± 30%). The aected members in MEN 2B families develop MTC (100% of cases) and Pheo (50% of cases) with an earlier age of tumor onset and developmental abnormalities such as ganglioneuromatosis, medullated corneal nerves, and marfanoid habitus. MTC is the only disease phenotype that develops in aected members of FMTC families, and it usually develops at a later stage in life, compared to MTC onset in MEN 2A and MEN 2B patients. As shown in Figure 2 , all germline mutations identi®ed in the aected members of MEN 2 families are clustered in speci®c regions of RET: the cysteine-rich domain in exons 10 and 11, or the tyrosine kinase domains in exons 13 ± 16. In addition to the mutations listed in Figure 2 , which account for mutations identi®ed in more than 95% of MEN 2 families, double mutations have been found in rare MEN 2 families, such as V804M/R844L in FMTC, V804M/Y806C in MEN 2B, and C634R/A640G in MEN 2A (Tessitore et al., 1999; Bartsch et al., 2000; Iwashita et al., 2000) .
Except for the mutations of codons 790 ± 1, which have not been tested, all RET/MEN2 mutants act as dominant oncoproteins with constitutive tyrosine kinase activity and the ability to induce transformed foci in NIH3T3 cells (Ito et al., 1997; Pasini et al., 1997; Chappuis-Flament et al., 1998; Iwashita et al., 1999 Iwashita et al., , 2000 . However, the mechanisms of RET oncogenic activations appear to be quite dierent among dierent mutations. For patients with MEN2A syndrome, most mutations are found in the cysteinerich region of the extracellular domain, changing a cysteine residue to a non-cysteine residue. It is believed Figure 2 Schematic representation of the RET gene showing the codons identi®ed in MEN 2 families (modi®ed from the review by Eng, 1999) . dup: duplication that these cysteine residues are normally involved in intramolecular disul®de bonds in wild-type RET. Therefore, the mutation of a cysteine residue to a non-cysteine residue in RET/2A leaves an unpaired cysteine residue in RET/2A monomer to form an intermolecular disul®de bond with another RET/2A monomer. Therefore, this type of mutation mimics the eect of ligand binding such that RET/2A is constitutively dimerized and activated . For patients with the MEN2B syndrome, 98% of them have a speci®c mutation changing Met 918 to Thr (M918T) in the kinase domain. Although the RET/2B receptor remains as a monomer in the absence of ligand binding, the M918T mutation activates its tyrosine kinase activity and alters its substrate speci®city . Consequently, RET/ 2B remains responsive to its ligands, and therefore, temporal and spatial expression of the neurotropic factors of GDNF family may further in¯uence the clinical phenotypes of MEN 2B patients. The dierences in the mechanism of oncogenic activation between RET/2A and RET/2B may help to uncover the underlying signaling pathways that are responsible for the phenotypic divergences between MEN 2A and MEN 2B patients.
Shortly after the identi®cation of RET as the susceptibility gene for MEN 2 disease, DNA-based genetic testing for RET mutation became the standard of care for MEN 2 families (reviewed in Eng, 1999) . MEN 2 is an autosomal dominant disease; therefore, ®rst-degree relatives of aected individuals are at 50% risk of inheriting the mutated gene. The presymptomatic DNA-based testing allows one-time blood testing to identify the gene carriers of MEN 2 family, instead of a life-long annual screening for the disease phenotypes. Once the gene carriers are identi®ed, prophylactic thyroidectomy is recommended as almost all the gene carriers in MEN 2 families eventually develop MTC, which can be lethal. However, the timing of surgical intervention may depend on the type of RET mutation identi®ed. Earlier surgical intervention is advocated for individuals carrying MEN 2B mutations and later surgical intervention preceded by annual biochemical surveillance is advocated for individuals carrying FMTC mutations. For individuals carrying the C634R mutation, screening for the presence of Pheo and PTH should be rigorously pursued. Finally, RET testing can be helpful in determining if an apparently sporadic MTC case is hereditary or truly nonhereditary.
Interestingly, the level of in vitro transforming activity of RET mutants appears to be correlated with the clinical phenotypes. RET mutants carrying the mutations found in MEN 2B and MEN 2A families have a higher transforming activity than RET mutants carrying the mutations found in FMTC . Among cysteine codon mutations, the cysteine 634 codon mutation appears to have much stronger transforming activity than non-634 cysteine codon mutations. This may be partially due to the marked reduction of RET mutants carrying non-634 cysteine mutation at the cell surface . Therefore, MEN 2A and FMTC may be a single genetic entity with dierent phenotypic manifestations as a consequence of dierences in the penetrance of dierent mutations. Furthermore, there may be a dierence in the transformation threshold among dierent tissues, such that thyroid C-cells have the lowest threshold and parathyroid cells have the highest threshold. Alternatively, the expression levels of RET may be dierent among the aected tissues in MEN 2 disease. Indeed, in screening for RET mutations in sporadic cancers relevant to MEN 2 disease, the frequency of RET mutations is highest in sporadic MTC, followed by sporadic Pheo, but absent in parathyroid tumors (Uchino et al., 1999; Asai et al., 1999; Krijger et al., 2000) . However, this theory can not explain the phenotypic variations among dierent families with the same mutation or even dierent aected individuals within a family (reviewed in Ponder, 1999) .
The phenotypes associated with RET mutations in MEN 2 disease, as well as the pattern of RET expression in development (Pachnis et al., 1993; Tsuzuki et al., 1995) and the phenotypes of the RET knockout mouse (Schuchardt et al., 1994) , indicate that RET plays important roles in a diverse set of tissues. Therefore, the eects of RET mutations are likely to dier among dierent cell types. In immortalized NIH3T3 mouse ®broblasts, RET activation leads to a transformed phenotype . In SK-N-MC neuroepithelioma cells, RET activation leads to lamellipodia formation (van Weering and Bos, 1997), cell scattering, growth inhibition and loss of anchorage-independent growth (van Puijenbroek et al., 1997). In PC12 rat pheochromocytoma cells, RET activation induces the expression of neuron-speci®c genes, accompanied by the loss of responsiveness to growth-inhibitory physiological signals (Califano et al., 1996) . For embryonic kidneys in organ culture, RET activation stimulates branching and proliferation . In Xenopus oocytes, RET activation induces meiotic maturation . While these studies are informative, it is pertinent to investigate the cellular eects of RET activation in cells relevant to MEN 2 disease under physiological conditions. Two dierent transgenic mouse models were generated to study the biological eects of MEN 2 mutations in RET on thyroid C-cells (Michiels et al., 1997; Acton et al., 2000) . Most of the transgenic mice expressing RET/2A (C634R) driven by a 1.7 kb calcitonin gene-related peptide/calcitonin (CGRP/CT) gene promoter did develop C cell hyperplasia (CCH) and subsequently multifocal and bilateral MTC. Among three independent lines established, one developed CCH at 3 weeks and MTC at 8 weeks with complete penetrance; the other two lines developed CCH at 6 months and MTC at 14 months with complete penetrance in only one of the two lines (Michiels et al., 1997) . For transgenic mice expressing RET/2B (M918T) driven by a 1.5 kb human calcitonin gene promoter, three out of eight founders had macroscopic bilateral MTC at 20 ± 22 months of age, two founders had nodular CCH at 22 months of age, and the remaining three founders did not show evidence of thyroid pathology at 20 ± 22 months of age. In the transgenic line established from a founder that developed MTC, 77% of the transgenic mice had detectable basal plasma CT levels, and two out of 23 mice developed MTC (Acton et al., 2000) . Taken together, the phenotypes of both CGRP/CT-MEN 2A transgenic mice and CT-MEN 2B transgenic mice mimic MTC in MEN 2 disease in that: (a) CCH precedes the development of MTC; (b) increased basal plasma levels of CT can serve as indicators of CCH and MTC; and (c) the variable latency period for MTC development suggests that additional oncogenic events are required for progression to MTC. Comparing the phenotypes of these two transgenic mice, one may conclude that RET/2A appears to be a stronger transforming gene for thyroid C-cells than RET/2B. However, it is important to note that: (a) the promoter used to drive the transgene expression is dierent between these two transgenic mice; (b) the copy number of transgene integrated may be dierent between RET/2A and RET/2B transgenic mice; and (c) while the same strain of mice was used to generate the transgenic founders (C57BL66DBA2), the transgenic lines were established in dierent strains of mice (C57BL6 for RET/2A mice versus DBA2 for RET/2B mice).
Both RET/2A and RET/2B transgenic mice carried RET cDNA encoding the RET9 isoform driven by a heterologous promoter. While both transgenic mice demonstrated the transforming activity of RET/2A and RET/2B in thyroid C-cells, these two animal models are limited in that the heterologous promoter may act very dierently from the RET promoter. Furthermore, the biological eects of the other two isoforms, RET51 and RET43, expressed in thyroid C-cells were not investigated. To overcome these limitations, a mouse model of MEN 2B was generated by introduction of the M918T mutation into the mouse RET gene (SmithHicks et al., 2000) . Heterozygous MEN 2B mice displayed C-cell hyperplasia and chroman cell hyperplasia that rarely progressed to Pheo. Homozygotes displayed an earlier incidence and increased severity of C-cell hyperplasia and chroman cell hyperplasia, which invariably progressed to Pheo, as well as male infertility. While the homozygotes did not develop ganglioneuromas of the intestinal tract or mucosa, they did display ganglioneuromas of the adrenal medulla and enlargement of associated sympathetic ganglia. Surprisingly, the homozygotes did not display any developmental defects attributable to altered substrate speci®city. Therefore, while RET(M918T) might gain new substrates, it either retains all of the normal substrates or loses those substrates that are not essential for the development of the kidneys or enteric nervous system (ENS) (SmithHicks et al., 2000) . Although this animal model has the genetic predisposition that completely mimics MEN 2B in humans, the phenotypes observed in this animal model are not identical to the clinical phenotypes observed in humans. Therefore, additional genes that modify the disease phenotypes of MEN 2 may exist in the strain of mice used, or the susceptibility of the relevant tissues to RET mutations may be dierent between humans and mice.
The nature and spectrum of RET mutations in MEN 2 are summarized (Figure 2 ). RET mutants carrying MEN 2 mutations are dominant oncoproteins as the wild-type RET allele is usually retained and expressed in tumor tissues. However, the mechanisms of RET/ MEN2 oncogenic activation may be due to constitutive dimerization or altered substrate speci®city. Clinical management for MEN 2 families has been dictated and greatly improved by presymptomatic DNA-based RET mutation testing. Prophylactic thyroidectomy is advocated for the gene carriers of MEN 2 families since the mortality in MEN 2 patients is mainly caused by MTC metastases. However, the timing of surgical intervention for MTC is still a subject of debate as the age of onset for MTC varies signi®cantly among aected individuals. Furthermore, the incomplete penetrance of Pheo and PTH warrants annual screening for these two diseases. Animal models of MTC induced by RET/2A or RET/2B as well as an animal model of MEN 2B are available. Further investigations of the signaling pathways activated by RET with dierent mutations in MEN 2 relevant tissues, such as thyroid C-cells, adrenal chroman cells, and parathyroid cells, are essential to understand the morphogenetic mechanisms underlying the phenotypic divergences of RET activation in dierent cells. Eventually, it may become possible to prevent the occurrence of the relevant tumors in MEN 2 patients.
RET interacting proteins and downstream signaling pathways
The general scheme for receptor tyrosine kinase (RTK) activated signal transduction begins with ligandinduced dimerization, activation of tyrosine kinase activity, and autophosphorylation of the cytoplasmic domain (reviewed in Schlessinger and Ullrich, 1992) . Tyrosine phosphorylation is crucial for RTK signaling, as the phosphopeptide motifs, composed of a phosphotyrosine residue (pY) within a particular sequence context, serve as speci®c binding sites to recruit various cytoplasmic target proteins that contain a SH2 domain or PTB domain. As most RTKs have multiple tyrosines to be phosphorylated, the activated receptor is coupled to several downstream biochemical pathways that lead to pleiotropic cellular responses. Recently, it has become apparent that the signaling speci®city of a given RTK is not only dictated by the phosphopeptide motifs of the RTK, but also in¯uenced by the assembly of speci®c signaling complexes by various scaold, anchoring, and adaptor proteins in a speci®c cell type (reviewed in Pawson and Scott, 1997) . Following this scenario, many investigators have identi®ed and characterized the pY-mediated signaling pathways mediated by RET activation in dierent cells (reviewed in van Weering and Bos, 1998) .
As shown in Figure 3 , RET has 10 tyrosine residues in the kinase domain, two in the juxtamembrane domain, one in the kinase insert, and three in the COOH-terminal tail (the long isoform of RET has two extra tyrosine residues in the COOH-terminus). Among the tyrosine residues located outside the kinase domain, Y687, Y826, Y1015, Y1029, and Y1062, have been shown to be phosphorylated in both RET/2A and RET/2B, while Y1096 is phosphorylated in RET/2A but not in RET/2B (Liu et al., 1996) . Takahashi and colleagues have shown that the substitutions of tyrosine with phenylalanine, Y905F and Y864/952F, resulted in severe impairment of the kinase activity in RET/2A and RET/2B, respectively , and that Y1062F, but not Y1015F, Y1090F, or Y1096F, markedly impaired the transforming activity of both RET/2A and RET/2B in immortalized NIH3T3 mouse ®broblasts . In contrast, others have shown that the mutation corresponding to Y1015F in RET/2A abolished RET/ PTC2 transforming activity in NIH3T3 cells (Borrelo et al., 1996) . However, the mitogenic signaling induced by RET/PTC2 was impaired by the mutation corresponding to Y1062F in RET/2A, but not by the mutation corresponding to Y905F or Y1015F in RET/ 2A (Durick et al., 1996) . Taken together, subtle dierences in protein conformation may result when RET is activated by ligand binding, MEN2A mutation, MEN2B mutation, or RET/PTC rearrangement. Consequently, dierent tyrosine residues may become phosphorylated, therefore, a dierent set of pYmediated signaling pathways may be generated by dierent forms of RET activation.
Several candidate proteins, which include PLCg, Shc, Grb2, Grb10, Enigma, paxillin, and an uncharacterized 23-kDa protein, have been proposed to participate in RET-activated signaling pathways (reviewed in van Weering and Bos, 1998; Romano et al., 1994) . The pY binding sites for Grb7/Grb10, PLCg, Shc/Enigma, and Grb2 have been identi®ed to be Y905, Y1015, Y1062, and Y1096, respectively (see Figure 3) . Both Shc and Grb2 are known to be important for the activation of Ras/MAPK pathways. The interaction between RET/ PTC2 and Enigma has been shown to play an important role in the proper subcellular localization of RET/PTC2 to the cell periphery (Durick et al., 1998) . In addition to serving as the docking site for Shc and Enigma, pY1062 was found to be also important for the activation of the PI3K/Akt pathway, which is important for RET/2B transforming activity (Segouf®n-Cariou and Billaud, 2000) . It has been shown that RET/2B had increased levels of PI3K activation . Novel substrates that interact with Crk and Nck are found to be phosphorylated by RET/2B activation (Bocciardi et al., 1997) . However, some of these protein ± protein interactions were only demonstrated by in vitro binding. Moreover, most studies were performed in immortalized mouse ®bro-blasts, which are physiologically irrelevant to RET function in vivo. The signaling protein complexes coupled with activated RET are likely to be dierent among dierent tissues. Therefore, it remains a major challenge to determine the downstream signaling pathways mediated by these RET-binding proteins, and their contributions to the cellular eects of RET activation on cells relevant to the physiological and pathological actions of RET.
RET induced signaling pathways have been mainly studied by either transfection of cultured cells with constitutively activated RET mutants (RET/PTC, RET/2A), or by ligand-induced RET activation in cells expressing EGFR/RET chimeric receptor or wildtype RET. In general, the signaling pathways activated by RET include Ras/MAPK, phosphoinositol-3-kinase (PI3K), Jun N-terminal kinase (JNK), and PLC g dependent pathways (reviewed in Airaksinen et al., 1999) . However, RET induced signaling pathways appear to be cell-type speci®c. In Xenopus oocytes, RET/PTC induced maturation appears to be mediated by Ras activation . In PC-12 cells, ERK-, cAMP-responsive element binding protein (CREB)-, and JUN-mediated signaling pathways are activated by RET activation, and these signaling pathways appear to be mediated by both pY905 and pY1062 (Xing et al., 1998) . Among these signaling pathways, signaling through Ras has been determined to be essential for RET-induced cell dierentiation in PC12 cells . The unresponsiveness of PC-12 cells to nerve growth factor induced by RET activation is due to the failure of nuclear translocation of ERK (Colocci-D' Amato et al., 2000) . In NR6 ®broblasts expressing EGFR/RET, RET activation induces Ras activation, but fails to activate the ERK2 signaling pathway or to induce PI3K activity in NIH3T3 transfectants . In human neuroblastoma cells expressing either exogenous or endogenous RET, RET activation not only induces the activation of the Ras/MAPK pathway, but also induces PI3K activity (van Weering et al., 1995; Worby et al., 1996) . In neurons, GDNF-induced RET activation activates Ras/MAPK, PI3K/Akt, and JNK pathways (Airaksinen et al., 1999) . However, the Ras/MAPK pathway appears to be necessary for survival and neurite growth stimulating actions. PI3K signaling independent of Akt is required for lamellipodia formation, which is implicated in neuritogenesis and dierentiation of cultured dopaminergic neurons. Both PI3K/Akt and JNK pathways are essential for neurotrophindependent neuronal survival.
The biological eects of RET activation in dierent cells are believed to be mediated by dierent RETbinding proteins and associated downstream signaling pathways. Most of the signaling transduction studies are performed using established cell lines. To date, little is known about RET signaling pathways in thyroid follicular cells, thyroid C-cells, adrenal chroman cells, and parathyroid cells, etc. Most, if not all, of the signaling pathways activated by RET are mediated by the protein complexes recruited by dierent RET phosphotyrosines. Therefore, it will be of physiological signi®cance and therapeutic importance to identify pYmediated signaling pathways that are responsible for the cellular eects induced by RET activation in relevant cells. Identi®cation and characterization of the signaling proteins and the physiological targets that participate in the identi®ed pY-mediated signaling pathways may help us to develop novel strategies to Figure 3 Tyrosine residues in the intracellular domain of RET with details on tyrosine phosphorylation, mutation analysis, and binding proteins. P: phosphorylated tyrosine residues in RET/2A and RET/2B oncoproteins. Y: tyrosine residue. M: mutation of tyrosine residue to phenylalanine residue decreases PTC2 mitogenicity. T/2A, T/2B, T/2A,B and T/PTC2: mutation of tyrosine residue to phenylalanine residue decreases the transforming activity of RET/2A, RET/2B, both RET/2A and RET/2B, and RET/PTC2 oncoproteins. The docking sites for Grb10, PLCg, Shc, Enigma, and Grb2 are indicated prevent or to treat human PCs and MEN 2 diseases, as well as the sporadic cancers relevant to MEN 2 disease.
Concluding remarks
In this review, we see that the correlation of RET activation with clinical properties of human cancers has provided many hypotheses to be tested by biochemical and functional studies. On the other hand, the biochemical and functional studies of RET activation in cultured cells and genetically-engineered animals have provided much insight that translates into improved care for patients with diseases associated with RET activation. While the cellular eects as well as the associated signaling pathways induced by dierent forms of RET activation may be dierent in dierent cells, several common signaling pathways are expected among dierent cells with dierent forms of RET activation. For example, the study of RET/PTCinduced signaling pathways in thyroid follicular cells may also provide valuable information regarding RET/ 2A-induced signaling pathways in MEN2A aected tissues. A thorough understanding of the signaling pathways mediated by RET activation in dierent cells will prove to have an impact on the clinical management of human diseases, not only PCs and MEN 2 disease, but also Hirschprung's disease and a variety of neurodegenerative diseases.
